Publications | PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977) PubMed=6935474; DOI=10.1093/jnci/66.2.239 Wright W.C., Daniels W.P., Fogh J. Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis. J. Natl. Cancer Inst. 66:239-247(1981) PubMed=7017212; DOI=10.1093/jnci/66.6.1003 Pollack M.S., Heagney S.D., Livingston P.O., Fogh J. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66:1003-1012(1981) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=2823272; DOI=10.1073/pnas.84.21.7716; PMCID=PMC299371 Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987) PubMed=3040234 Rodan S.B., Imai Y., Thiede M.A., Wesolowski G., Thompson D., Bar-Shavit Z., Shull S., Mann K., Rodan G.A. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res. 47:4961-4966(1987) PubMed=2233717; DOI=10.1128/mcb.10.11.5772-5781.1990; PMCID=PMC361354 Diller L., Kassel J., Nelson C.E., Gryka M.A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781(1990) PubMed=8617485; DOI=10.1016/S0046-8177(96)90115-X Scotlandi K., Serra M., Manara M.C., Benini S., Sarti M., Maurici D., Lollini P.-L., Picci P., Bertoni F., Baldini N. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Hum. Pathol. 27:408-416(1996) PubMed=10763916; DOI=10.1023/A:1006623001465 Jia S.-F., Worth L.L., Kleinerman E.S. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis 17:501-506(1999) PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459 Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G. Short tandem repeat profiling provides an international reference standard for human cell lines. Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001) PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4 Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Boecker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet. Cytogenet. 140:145-152(2003) PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809 Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R., Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B., Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G., Gabbert H.E., Poremba C. Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res. 64:3395-3405(2004) PubMed=15736406 Pautke C., Schieker M., Tischer T., Kolk A., Neth P., Mutschler W., Milz S. Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts. Anticancer Res. 24:3743-3748(2004) PubMed=15939397; DOI=10.1016/j.bbrc.2005.05.097 Hausser H.-J., Brenner R.E. Phenotypic instability of Saos-2 cells in long-term culture. Biochem. Biophys. Res. Commun. 333:216-222(2005) PubMed=16888811; DOI=10.1002/jcb.21073 Moneo V., Serelde B.G., Fominaya J.M., Martinez-Leal J.F., Blanco-Aparicio C., Romero L., Sanchez-Beato M., Cigudosa J.C., Tercero J.C., Piris M.A., Jimeno J.M., Carnero A. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J. Cell. Biochem. 100:339-348(2007) PubMed=17354236; DOI=10.1002/ijc.22643 Muller C.R., Paulsen E.B., Noordhuis P., Pedeutour F., Saeter G., Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int. J. Cancer 121:199-205(2007) PubMed=17431109; DOI=10.1158/1535-7163.MCT-06-0729 Moneo V., Serelde B.G., Leal J.F.M., Blanco-Aparicio C., Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A. Levels of p27(kip1) determine Aplidin sensitivity. Mol. Cancer Ther. 6:1310-1316(2007) PubMed=17981215; DOI=10.1016/j.cancergencyto.2007.08.003 Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M. Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet. Cytogenet. 179:52-61(2007) PubMed=19787792; DOI=10.1002/gcc.20717 Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49:40-51(2010) PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113 Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010) PubMed=21519327; DOI=10.1038/labinvest.2011.72 Mohseny A.B., Machado I., Cai Y.-P., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab. Invest. 91:1195-1205(2011) PubMed=22075555; DOI=10.1158/0008-5472.CAN-11-2778; PMCID=PMC3833671 Huang G.-X., Yu L., Cooper L.J.N., Hollomon M., Huls H., Kleinerman E.S. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 72:271-281(2012) PubMed=23144859; DOI=10.1371/journal.pone.0048262; PMCID=PMC3492335 Kresse S.H., Rydbeck H., Skarn M., Namlos H.M., Barragan-Polania A.H., Cleton-Jansen A.-M., Serra M., Liestol K., Hogendoorn P.C.W., Hovig E., Myklebost O., Meza-Zepeda L.A. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS ONE 7:E48262-E48262(2012) PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030 Lu Y.-H., Soong T.D., Elemento O. A novel approach for characterizing microsatellite instability in cancer cells. PLoS ONE 8:E63056-E63056(2013) PubMed=24758355; DOI=10.1186/1471-2407-14-281; PMCID=PMC4023704 Moneo V., Serelde B.G., Blanco-Aparicio C., Diaz-Uriarte R., Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A. Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer 14:281.1-281.10(2014) PubMed=25031706; PMCID=PMC4097260 Du L., Fan Q.-M., Tu B., Yan W., Tang T.-T. Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2. Int. J. Clin. Exp. Pathol. 7:2871-2882(2014) PubMed=26320182; DOI=10.18632/oncotarget.5177; PMCID=PMC4745740 Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J.J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C. Characterization of the metastatic phenotype of a panel of established osteosarcoma cells. Oncotarget 6:29469-29481(2015) PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074; PMCID=PMC4636476 Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E., Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J., Harris E., Monks A., Morris J. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol. Cancer Ther. 14:2452-2462(2015) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=29334376; DOI=10.1038/nm.4475; PMCID=PMC5803371 Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat. Med. 24:176-185(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402.e16(2020) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |